WO2011110838A3 - Therapeutic treatments and screening methods using p63 - Google Patents

Therapeutic treatments and screening methods using p63 Download PDF

Info

Publication number
WO2011110838A3
WO2011110838A3 PCT/GB2011/050446 GB2011050446W WO2011110838A3 WO 2011110838 A3 WO2011110838 A3 WO 2011110838A3 GB 2011050446 W GB2011050446 W GB 2011050446W WO 2011110838 A3 WO2011110838 A3 WO 2011110838A3
Authority
WO
WIPO (PCT)
Prior art keywords
screening methods
therapeutic treatments
prostate cancer
cells
expressed
Prior art date
Application number
PCT/GB2011/050446
Other languages
French (fr)
Other versions
WO2011110838A2 (en
Inventor
Amanda Nicholl
April Fraser
Norman Maitland
Anne Collins
Original Assignee
Procure Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1003722.4A external-priority patent/GB201003722D0/en
Priority claimed from GBGB1007455.7A external-priority patent/GB201007455D0/en
Priority claimed from GBGB1021384.1A external-priority patent/GB201021384D0/en
Application filed by Procure Therapeutics Limited filed Critical Procure Therapeutics Limited
Publication of WO2011110838A2 publication Critical patent/WO2011110838A2/en
Publication of WO2011110838A3 publication Critical patent/WO2011110838A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

We disclose therapeutic agents that target p63 expressed by prostate cancer cells and/or prostate cancer stem/progenitor cells and including combination therapies useful in the treatment of prostate cancer.
PCT/GB2011/050446 2010-03-08 2011-03-08 Differentiation factor WO2011110838A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1003722.4 2010-03-08
GBGB1003722.4A GB201003722D0 (en) 2010-03-08 2010-03-08 Differentiation factor
GB1007455.7 2010-05-05
GBGB1007455.7A GB201007455D0 (en) 2010-05-05 2010-05-05 Differential factor
GB1021384.1 2010-12-16
GBGB1021384.1A GB201021384D0 (en) 2010-12-16 2010-12-16 Differentiation factor

Publications (2)

Publication Number Publication Date
WO2011110838A2 WO2011110838A2 (en) 2011-09-15
WO2011110838A3 true WO2011110838A3 (en) 2012-05-18

Family

ID=44563924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/050446 WO2011110838A2 (en) 2010-03-08 2011-03-08 Differentiation factor

Country Status (1)

Country Link
WO (1) WO2011110838A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331648A (en) * 1979-12-05 1982-05-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy
JPH0840888A (en) * 1994-07-28 1996-02-13 Ajinomoto Co Inc Antitumor agent against myeloma-based tumor
WO1997029759A1 (en) * 1996-02-14 1997-08-21 Zambon Group S.P.A. Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin
WO2003077900A1 (en) * 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
WO2008045344A2 (en) * 2006-10-06 2008-04-17 The General Hospital Corporation Methods to determine responsiveness to cisplatin treatment
WO2010015590A1 (en) * 2008-08-04 2010-02-11 Universita' Degli Studi Di Palermo Organotin(iv) complexes with n-acetylcysteine possessing antitumoral activity, process for their production and their use
WO2010039679A1 (en) * 2008-09-30 2010-04-08 The Hospital For Sick Children Compositions for proliferation of cells and related methods
WO2011090741A2 (en) * 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5978740A (en) 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
WO2007037782A2 (en) 2005-02-08 2007-04-05 The University Of North Carolina At Chapel Hill Method for treating prostate conditions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331648A (en) * 1979-12-05 1982-05-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services N-Acetyl-cysteine protects against cardiac damage from subsequently-administered cardio-toxic anthra-cycline in cancer therapy
JPH0840888A (en) * 1994-07-28 1996-02-13 Ajinomoto Co Inc Antitumor agent against myeloma-based tumor
WO1997029759A1 (en) * 1996-02-14 1997-08-21 Zambon Group S.P.A. Pharmaceutical composition enabling to inhibit cancer metastasis formation containing n-acetyl-cysteine and doxorubicin
WO2003077900A1 (en) * 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
WO2008045344A2 (en) * 2006-10-06 2008-04-17 The General Hospital Corporation Methods to determine responsiveness to cisplatin treatment
WO2010015590A1 (en) * 2008-08-04 2010-02-11 Universita' Degli Studi Di Palermo Organotin(iv) complexes with n-acetylcysteine possessing antitumoral activity, process for their production and their use
WO2010039679A1 (en) * 2008-09-30 2010-04-08 The Hospital For Sick Children Compositions for proliferation of cells and related methods
WO2011090741A2 (en) * 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199616, Derwent World Patents Index; AN 1996-157002, XP002665835 *
FUKUSHIMA HIROSHI ET AL: "Loss of Delta Np63 alpha Promotes Invasion of Urothelial Carcinomas via N-Cadherin/Src Homology and Collagen/Extracellular Signal-Regulated Kinase Pathway", CANCER RESEARCH, vol. 69, no. 24, December 2009 (2009-12-01), pages 9263 - 9270, XP002665837, ISSN: 0008-5472 *
GU ET AL: "p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck", CANCER LETTERS, NEW YORK, NY, US, vol. 263, no. 1, 14 January 2008 (2008-01-14), pages 26 - 34, XP022561631, ISSN: 0304-3835 *
MURATA ET AL: "p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 83, no. 3, 14 November 2007 (2007-11-14), pages 367 - 376, XP022344808, ISSN: 0014-4800, DOI: 10.1016/J.YEXMP.2007.03.006 *
SANTA CRUZ BIOTECHNOLOGY: "p63 siRNA (h): sc-36161", XP002665836, Retrieved from the Internet <URL:http://datasheets.scbt.com/sc-36161.pdf> [retrieved on 20111213] *

Also Published As

Publication number Publication date
WO2011110838A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2012051210A3 (en) Mesenchymal stem cells and related therapies
MY186591A (en) Methods for increasing efficacy of folri cancer therapy
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
AU2011328009A8 (en) Compounds and methods for treating pain
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
MX370720B (en) Anti-gdf15 antibodies.
AR082340A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
MX356525B (en) Aav -vectors for use in gene therapy of choroideremia.
JOP20130273B1 (en) Glucosylceramide synthase inhibitors
EA201101522A1 (en) METHODS OF TREATMENT OF DISEASES WITH THE USE OF EPIMETABOLIC SWITCH (COENZIM Q10)
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
IN2012DN02046A (en)
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2012170776A3 (en) Methods of determining a patient&#39;s prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2011135303A3 (en) Ubiquitination modulators
MX2015012922A (en) Cancer treatment using antibodies that bing cell surface grp78.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2012008958A (en) Neuregulin antagonists and use thereof in treating cancer.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
MX2014001766A (en) Neuregulin antibodies and uses thereof.
MX2014001393A (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11722136

Country of ref document: EP

Kind code of ref document: A2